# HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct04619004/  
OnCo record `nct04619004` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Patritumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.

## Summary

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT04619004 by Daiichi Sankyo, with 277 participants enrolled, started 2021-02-02 and due to reach its primary completion in 2022-11-21. Interventions recorded: Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration). Conditions listed: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04619004
- Phase: 2
- Setting: HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Daiichi Sankyo
- Enrolled: 277

## Sources

- ClinicalTrials.gov NCT04619004: https://clinicaltrials.gov/study/NCT04619004

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct04619004.json